Effects of Community-Wide Vaccination with PCV-7 on Pneumococcal Nasopharyngeal Carriage in The Gambia: A Cluster-Randomized Trial

Roca, Anna; Hill, Philip C.; Townend, John; Egere, Uzo; Antonio, Martin; Bojang, Abdoulie; Akisanya, Abiodun; Litchfield, Teresa; Nsekpong, David E.; Oluwalana, Claire; Howie, Stephen R. C.; Greenwood, Brian; Adegbola, Richard A.
October 2011
PLoS Clinical Trials;Oct2011, Vol. 8 Issue 10, Special section p1
Academic Journal
Background: Introduction of pneumococcal conjugate vaccines (PCVs) of limited valency is justified in Africa by the high burden of pneumococcal disease. Long-term beneficial effects of PCVs may be countered by serotype replacement. We aimed to determine the impact of PCV-7 vaccination on pneumococcal carriage in rural Gambia. Methods and Findings: A cluster-randomized (by village) trial of the impact of PCV-7 on pneumococcal nasopharyngeal carriage was conducted in 21 Gambian villages between December 2003 to June 2008 (5,441 inhabitants in 2006). Analysis was complemented with data obtained before vaccination. Because efficacy of PCV-9 in young Gambian children had been shown, it was considered unethical not to give PCV-7 to young children in all of the study villages. PCV-7 was given to children below 30 mo of age and to those born during the trial in all study villages. Villages were randomized (older children and adults) to receive one dose of PCV-7 (11 vaccinated villages) or meningococcal serogroup C conjugate vaccine (10 control villages). Cross-sectional surveys (CSSs) to collect nasopharyngeal swabs were conducted before vaccination (2,094 samples in the baseline CSS), and 4-6, 12, and 22 mo after vaccination (1,168, 1,210, and 446 samples in CSS-1, -2, and -3, respectively). A time trend analysis showed a marked fall in the prevalence of vaccine-type pneumococcal carriage in all age groups following vaccination (from 23.7% and 26.8% in the baseline CSS to 7.1% and 8.5% in CSS-1, in vaccinated and control villages, respectively). The prevalence of vaccine-type pneumococcal carriage was lower in vaccinated than in control villages among older children (5 y to ,15 y of age) and adults ($15 y of age) at CSS-2 (odds ratio [OR] = 0.15 [95% CI 0.04-0.57] and OR = 0.32 [95% CI 0.10-0.98], respectively) and at CSS-3 (OR = 0.37 [95% CI 0.15-0.90] for older children, and 0% versus 7.6% for adults in vaccinated and control villages, respectively). Differences in the prevalence of non-vaccine-type pneumococcal carriage between vaccinated and control villages were small. Conclusions: Vaccination of Gambian children reduced vaccine-type pneumococcal carriage across all age groups, indicating a "herd effect" in non-vaccinated older children and adults. No significant serotype replacement was detected.


Related Articles

  • PCV-10 vax cost effective vs PCV-13.  // PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p7 

    The article discusses a cost-utility analysis conducted in an Argentine healthcare system in 2011 which shows that pneumococcal 10-valent vaccine conjugate (PCV-10) is better value for money for routine child immunisation than pneumococcal 13-valent-CRM197 vaccine conjugate (PCV-13).

  • Cost a barrier for self-paid vaccination in Poland.  // PharmacoEconomics & Outcomes News;11/2/2013, Issue 690, p5 

    The article discusses the results of a study which appeared in an article by M Ganczak et al. in the October 8, 2013 issue of "Vaccine," revealing that immunisation coverage for self-paid vaccines among children aged 0-5 years in Poland is largely shaped by the cost of the vaccine.

  • Recommended Childhood and Adolescent Immunization Schedule/ United States, 2003.  // MMWR: Morbidity & Mortality Weekly Report;1/31/2003, Vol. 52 Issue 4, pQ1 

    Presents information on the recommended childhood and adolescent immunization schedule in the U.S. as of January 2003. Types of vaccine administered to children and adolescents; Reasons behind the deferral of some doses of pneumococcal conjugate vaccine; Details of the National Childhood...

  • Herd immunity in adults improves value of paediatric vax.  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p9 

    The article presents information on an economic analysis which found that when the herd immunity effect on adults is considered, the cost effectiveness of pneumococcal conjugate vaccine in U.S. children improves. The results of the analysis was presented at the 43rd Annual Meeting of the...

  • Reduction in erythromycin resistance in invasive pneumococci from young children in England and Wales. Henderson, Katherine L.; Muller-Pebody, Berit; Blackburn, Ruth M.; Johnson, Alan P. // Journal of Antimicrobial Chemotherapy (JAC);Feb2010, Vol. 65 Issue 2, p369 

    A letter to the editor is presented about a study of the effects of immunization with pneumococcal heptavalent conjugate vaccine (PCV7) based on data on pneumococcal bacteraemia and erythromycin susceptibility tests of children in England and Wales from 2000 to 2009.

  • Pneumococcal 7-valent CRM197 vaccine conjugate.  // Reactions Weekly;Aug2014, Vol. 1516 Issue 1, p154 

    An abstract of the article "Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway," by A. Steens and colleagues is presented.

  • Independent Nurse: Recent research indicates need for change to immunisation schedule. Polak, Monika // GP: General Practitioner;12/2/2005, p93 

    The article reports that the childhood immunisation schedule looks set for a significant overhaul in the light of recent research. Professor Keith Cartwright, a member of the Joint Committee on Vaccination and Immunisation said that immunological evidence suggested additional booster doses are...

  • A little shot of magic. Netherwood, Cathy // Australian Parents;Aug/Sep2005, p52 

    Discusses the benefits of immunization to children. Concerns of parents about the risks associated with vaccines; Schedule of vaccination in children; Information on some vaccines; Clinical background on whooping cough, pneumococcal and meningococcal diseases. INSET: Immunisation? Vaccination?...

  • New PCV7 recommendations.  // Infectious Diseases in Children;May2008, Vol. 21 Issue 5, p13 

    The article reports on the updated recommendations for the use of the 7-valent pneumococcal conjugate vaccine in children aged 24 to 59 months. The Pneumococcal Vaccines Work Group presented data regarding the safety and immunogenicity of PCV7 among children in this age group at the Advisory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics